BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26531831)

  • 1. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors.
    Ujj Z; Buglyó G; Udvardy M; Beyer D; Vargha G; Biró S; Rejtő L
    Pathol Oncol Res; 2016 Jan; 22(1):217-21. PubMed ID: 26531831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
    Frairia C; Aydin S; Audisio E; Riera L; Aliberti S; Allione B; Busca A; D'Ardia S; Dellacasa CM; Demurtas A; Evangelista A; Ciccone G; Francia di Celle P; Nicolino B; Stacchini A; Marmont F; Vitolo U
    Leuk Res; 2017 Oct; 61():10-17. PubMed ID: 28846953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
    Marani C; Clavio M; Grasso R; Colombo N; Guolo F; Kunkl A; Ballerini F; Giannoni L; Ghiggi C; Fugazza G; Ravetti JL; Gobbi M; Miglino M
    Leuk Res; 2013 Dec; 37(12):1606-11. PubMed ID: 23891447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.
    El Bordiny M; Al-Ghandour A; Abo Elwafa RA; Fayed O
    Clin Transl Oncol; 2019 Jul; 21(7):864-873. PubMed ID: 30506133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia.
    Andersson C; Li X; Lorenz F; Golovleva I; Wahlin A; Li A
    Diagn Mol Pathol; 2012 Dec; 21(4):225-33. PubMed ID: 23111196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients.
    Mossallam GI; Abdel Hamid TM; Mahmoud HK
    Hematology; 2013 Mar; 18(2):69-73. PubMed ID: 23394625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WT1 overexpression affecting clinical outcome in non-hodgkin lymphomas and adult acute lymphoblastic leukemia.
    Ujj Z; Buglyó G; Udvardy M; Vargha G; Biró S; Rejtő L
    Pathol Oncol Res; 2014 Jul; 20(3):565-70. PubMed ID: 24374862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
    Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
    Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
    Sakamoto Y; Mariya Y; Sasaki S; Teshiromori R; Oshikiri T; Segawa M; Ogura K; Akagi T; Kubo K; Kaimori M; Funato T
    Tohoku J Exp Med; 2009 Oct; 219(2):169-76. PubMed ID: 19776535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
    Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance].
    Zhang R; Sun HQ; Li G; Bai FY; Yang Y; Jing Q; Shi YJ; Yang JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):959-63. PubMed ID: 21867623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
    Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
    Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.